MEDI4736 + Tremelimumab

DRUG3 trials

Conditions

Gastric or Gastroesophageal Junction AdenocarcinomaRecurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHNRecurrent/Metastatic Squamous Cell Carcinoma of Head & Neck

Phase 1

A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

CompletedNCT02340975

MedImmune LLCGastric or Gastroesophageal Junction Adenocarcinoma

Start: 2015-03-31End: 2019-04-29Updated: 2020-06-09

Phase 2

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

CompletedNCT02319044

AstraZenecaRecurrent/Metastatic Squamous Cell Carcinoma of Head & Neck

Start: 2015-04-15End: 2020-07-06Updated: 2020-09-29

Phase 3

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

CompletedNCT02369874

AstraZenecaRecurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN

Start: 2015-09-09End: 2020-11-13Updated: 2021-02-10

Clinical Cancer Research2025-03-131 citations

Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.

2024-03-025 citations

591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data

Regular and Young Investigator Award Abstracts2022-11-01

269 Tumoral and peripheral landscape of Viral- versus Carcinogen-Driven Head and Neck Cancer

Regular and Young Investigator Award Abstracts2020-11-011 citations

Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.

Journal of Clinical Oncology2020-05-2027 citations

Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.

Journal of Clinical Oncology2020-05-207 citations

Overall survival modeling and association with serum biomarkers in durvalumab-treated patients with head and neck cancer.

Journal of Clinical Oncology2020-05-203 citations

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.

2020-04-12285 citations

EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Journal of Clinical Oncology2019-05-2039 citations

Correlation of angiogenic and immunomodulatory proteins with clinical outcomes of durvalumab (anti-PDL1) in recurrent/metastatic head and neck squamous cell carcinoma.

Journal of Clinical Oncology2019-05-20

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.

2019-01-1436 citations

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC

JAMA Oncology2018-11-01306 citations

Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.

Journal of Clinical Oncology2018-05-2014 citations

Early reduction in circulating tumor DNA (ctDNA) and survival in gastric cancer patients (pts) treated with durvalumab (D), tremelimumab (T), or durvalumab in combination with tremelimumab (D+T).

Journal of Clinical Oncology2018-05-203 citations

MEDI4736 + Tremelimumab

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers